



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/62, 5/00	A1	(11) International Publication Number: WO 91/17253 (43) International Publication Date: 14 November 1991 (14.11.91)
<p>(21) International Application Number: PCT/DK91/00116</p> <p>(22) International Filing Date: 30 April 1991 (30.04.91)</p> <p>(30) Priority data: 1064/90 30 April 1990 (30.04.90) DK</p> <p>(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only) : WIBERG, Finn, Christoph [DK/DK]; Vinkelvej 16, DK-3520 Farum (DK). OLSEN, Frank [DK/DK]; Christoffers Allé 139, DK-2800 Lyngby (DK). BOEL, Esper [DK/DK]; Lyngbakkevej 25, DK-2840 Holte (DK). KJELDSEN, Thomas, Børglum [DK/DK]; Kvædevej 73, DK-2830 Virum (DK). MØLLER, Niels, Peter, Hundahl [DK/DK]; Lyngen 20 A, DK-2800 Lyngby (DK).</p>		<p>(74) Common Representative: NOVO NORDISK A/S; Patent Department, Novo Allé, DK-2880 Bagsværd (DK).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.</p> <p>Published With international search report.</p>
<p>(54) Title: MAMMALIAN CELLS EXPRESSING A HYBRID RECEPTOR</p>		
<p>(57) Abstract</p> <p>Mammalian cells containing a hybrid DNA insert which comprises a first DNA sequence encoding part of the extracellular domain of a first cellular receptor and a second DNA sequence encoding part of the extracellular domain of second cellular receptor which is specific for a different ligand than the first cellular receptor have favourable growth properties in serum-containing as well as serum-free media.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

MAMMALIAN CELLS EXPRESSING A HYBRID RECEPTOR

FIELD OF INVENTION

The present invention relates to a cell expressing a hybrid between different cellular receptors and a process of producing
5 a desired polypeptide from the cell.

BACKGROUND OF THE INVENTION

Cell culture has been carried out for many years in order to investigate for instance the physiology of mammalian cells and the relationship between mammalian cells and other organisms
10 such as viruses as well as the impact of a large number of different compounds on the cells. The equipment traditionally used for cell culture includes glass vessels, petri dishes, T-flasks and the like. The media formulations used for cell culture experiments have been named for the persons who
15 developed them (often on a trial-and-error basis) or modified them in various ways, i.a. Ham, Dulbecco, Leibovitz, McCoy, Waymouth, Eagle, Iscove, etc.

These conventional media all contain serum which was found to make the cells grow at a reasonable rate for experimentation
20 purposes, and the serum which has generally been found to provide the best growth rate is foetal calf serum. The scarcity and variable quality of this serum has created serious problems for cell culture in that the experiments have often been difficult to reproduce.

25 Although other aspects of cell culture, in particular the equipment used to culture the cells on a larger scale, have undergone a rapid development in recent years, the composition of the standard media used for cultivation is substantially the same as in the early days of cell culture. Thus, the media
30 still have a high serum content.

Modern concepts of producing pharmaceuticals on the basis of cell culture require a stringent process control, not only with respect to purification, but also with respect to culture conditions. The use of serum in media is inconsistent with this requirement: due to its biological nature, the composition of serum varies from batch to batch resulting in variability of the cultivation process. Serum also represents the single most important source of unrelated protein present in the culture liquid, which can only be removed from the product of interest by laborious methods resulting in a lower yield of the product of interest. Moreover, serum is the single most important source of contamination of the cell culture with mycoplasma, bacteria or viruses, and costly as well as time-consuming measures have to be taken to remove these contaminants from the serum and to test for their absence.

It would therefore be highly desirable to omit serum from media used for mammalian cell culture. Attempts have been made to adapt cell lines already used in the production of pharmaceuticals or potentially useful cell lines to growth in serum-free media or media with a reduced serum content. It has, however, been observed that when adaptations to serum-free or low serum media have been made, this has been at the expense of growth performance, i.e. the cells grow at a slower rate than in serum-containing media, resulting in lower productivity and higher susceptibility to invading contaminants.

A cell line which is able to grow at an increased growth rate than normally observed in serum-containing media, not only in serum-containing media, but also in serum-free media would therefore be of great potential interest for cell culture in the pharmaceutical industry. By omitting serum, it would be simpler to purify the product of interest resulting in improved yields and purity, and a stable faster cell growth rate would lead to a high process productivity, i.e. because rapid-

growing cells would be less susceptible to infectious organisms.

SUMMARY OF THE INVENTION

It has surprisingly been found that cells with favourable growth properties in serum-containing as well as serum-free media may be obtained by introducing into the cells a DNA construct which comprises a hybrid DNA sequence coding for parts of two different cell surface receptors.

Accordingly, the present invention relates to a mammalian cell containing a hybrid DNA insert which comprises a first DNA sequence encoding part of the extracellular domain of a first cellular receptor and a second DNA sequence encoding part of the extracellular domain of a second cellular receptor which is specific for a different ligand than the first cellular receptor.

Cellular receptors which are typically located on cell surfaces mediate certain important cell to cell interactions involving the transmission of extracellular signals by the interaction with ligands. Such receptors are composed of an extracellular domain (in monomeric or dimeric form) which is capable of specifically recognizing and binding a particular ligand and which may have highly glycosylated and protease-resistant structure, a transmembrane domain which is responsible for anchoring the receptor in the cell membrane and which consists of a hydrophobic sequence of some 25 amino acids, and a cytoplasmic domain which is responsible for generating a cellular signal as a response to the binding of the ligand to the extracellular domain; the cytoplasmic domain(s) may define an enzymatic activity which is triggered by ligand binding.

The reason why hybrid receptors of the invention may promote the growth of cells (particularly in serum-free media) has not

yet been determined. It is, however, currently assumed that such hybrid receptor constructions provide a constant stimulation of the growth regulatory system of the cells so that their dependence on growth factors (e.g. those present in serum) is reduced. Furthermore, it is possible that hybrid receptors are less sensitive to non-activating ligands (e.g. degradation products or metabolites from the cells) and therefore less likely to be inhibited for binding than the natural receptor.

A number of naturally occurring receptors have previously been identified. Thus, Rubin et al., J. Immun. 135, 1985, pp. 3172-3177, describe the release of large quantities of the interleukin-2 receptor (IL-2-R) into the culture medium of activated T-cells. The DNA sequence coding for the insulin receptor has been published by A. Ullrich et al., Nature 313, 28 Feb. 1985, pp. 756-761, and S. Seino, Proc. Natl. Acad. Sci. USA 86, 1989, pp. 114-118. Similarly, the DNA sequence coding for the IGF-I receptor has been published by A. Ullrich et al., The EMBO J. 5(10), 1986, pp. 2503-2512.

European Patent Application, Publication No. 244 221 discloses receptors which are hybrids between the extracellular ligand-binding domain of one receptor fused to a heterologous reporter polypeptide which may be the cytoplasmic domain of another receptor.

B. Kobilka et al, Science 240, 3 June 1988, pp. 1310-1316, disclose chimeras between $\alpha 2$ and $\beta 2$ adrenergic receptors constructed by replacing DNA sequences encoding various parts of the membrane-spanning domain of one of the receptors by the DNA sequences encoding corresponding parts of the other receptor and expressing the sequences in Xenopus laevis oocytes.

I. Lax et al., The EMBO J. 8(2), 1989, pp. 421-427, disclose chimeras between chicken and human EGF receptors constructed by replacing DNA sequences encoding various parts of one of the

receptors by DNA sequences encoding the corresponding parts of the other receptor, and expressed on the surface of mammalian cells.

However, none of these prior publications discloses any use of either natural or hybrid receptors for promoting the growth of mammalian cells.

In the present context, the expression "specific for a different ligand" is intended to indicate that the second receptor specifically binds a ligand which, in a given organism, has a different biological function and/or activity than the ligand binding to the first receptor. The expression is intended to distinguish the present hybrid receptors from those described by, for instance, I. Lax et al., op. cit., which are hybrids of receptors specific for essentially the same ligand derived from two different organisms. The term "ligand" may be defined as a substance which, in nature, is capable of binding to a particular cellular receptor. Preferred ligands are those which act in a similar way as the natural ligand for the receptor in question (e.g. a hormone, growth factor, cytokine or cell adhesion molecule).

DETAILED DISCLOSURE OF THE INVENTION

In particular, the DNA insert introduced into the cell of the present invention is one in which the first DNA sequence (encoding part of the extracellular domain of the first receptor) encodes an exon or a fragment thereof, or in which the second DNA sequence (encoding part of the extracellular domain of the second receptor) encodes an exon or a fragment thereof. For the present purpose, either the first or the second DNA sequence may encode a ligand-binding site of the first or second receptor.

In a particularly preferred embodiment of the cell of the present invention, the DNA insert is one in which the DNA

sequences coding for the first and second receptors exhibit a high degree of homology in the organization and/or structure of their exons. This may be advantageous as it is possible to systematically substitute specific fragments from one receptor 5 for the corresponding fragments from the other receptor. When producing a cell of the invention, it may therefore be an advantage to initially replace one or more exons from one of the receptors by the corresponding exon or exons from the other receptor, and to test the growth properties of cells into which 10 the DNA construct coding for each hybrid has been introduced.

In this embodiment of the DNA insert introduced in the cell of the invention, a DNA sequence encoding one or more exons, or a fragment thereof, of the extracellular domain of the first receptor may be replaced by a DNA sequence encoding the 15 corresponding exon or exons, or fragment thereof, of the extracellular domain of the second receptor. Alternatively, a DNA sequence encoding one or more exons, or a fragment thereof, of the extracellular domain of the second receptor may be replaced by a DNA sequence encoding the corresponding exon or 20 exons, or fragment thereof, of the extracellular domain of the first receptor.

As indicated above, the parent receptors are cell surface receptors, in particular receptors for hormones, growth factors, cytokines or cell adhesion molecules. Thus, the 25 receptors may be selected from the group consisting of the insulin, insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor (TGF), including TGF- α and TGF- β , growth hormone and prolactin receptors. The hybrid receptor may 30 advantageously be one comprising at least part of the binding site for a ligand produced by the cell itself (e.g. containing the whole or part of the EGF binding site of the EGF receptor). This permits the cell to stimulate its own growth, thereby reducing the need for adding external growth promoting agents 35 to the culture medium in order to stimulate cell growth.

In the above-described preferred embodiment of the DNA insert of the invention, hybrids are constructed from receptors which exhibit the aforementioned homology in the overall organization of their DNA.

5 More specifically, in the DNA insert introduced in the cell of the invention, the DNA sequence coding for exon 2, or a fragment thereof, of the insulin receptor may be replaced by the DNA sequence coding for exon 2, or a fragment thereof, of the IGF receptor. Alternatively, the DNA sequence coding for
10 exon 3, or a fragment thereof, of the insulin receptor may be replaced by the DNA sequence coding for exon 3, or a fragment thereof, of the IGF receptor. In a further alternative embodiment, the DNA sequence coding for exons 2 and 3, or a fragment thereof, of the insulin receptor may be replaced by
15 the DNA sequence coding for exons 2 and 3, or a fragment thereof, of the IGF receptor.

In another embodiment of the DNA insert, the DNA sequence coding for exon 2, or a fragment thereof, of the IGF receptor may be replaced by the DNA sequence coding for exon 2, or a
20 fragment thereof, of the insulin receptor. Alternatively, the DNA sequence coding for exon 3, or a fragment thereof, of the IGF receptor may be replaced by the DNA sequence coding for exon 3, or a fragment thereof, of the insulin receptor. As a further alternative, the DNA sequence coding for exons 2 and 3,
25 or a fragment thereof, of the IGF receptor may be replaced by the DNA sequence coding for exons 2 and 3, or a fragment thereof, of the insulin receptor.

Similarly, a DNA sequence coding for exon 1 (preferably combined with exon 2 or a fragment thereof) or one or more of
30 exons 4-11 or fragments thereof of the insulin receptor may be replaced by the corresponding DNA sequence from the IGF receptor, or vice versa.

One example of a cell of the invention exhibiting favourable growth properties is one in which a DNA insert has been introduced, which has the partial DNA sequence shown in Fig. 4A-4F (encoding the extracellular domain of the hybrid receptor), or a suitable modification thereof. Suitable modifications of the DNA sequence may comprise nucleotide substitutions which do not give rise to another amino acid sequence of the hybrid polypeptide, but which facilitate the production of the polypeptide, or nucleotide substitutions which do give rise to a different amino acid sequence of the hybrid polypeptide. Other possible modifications may be insertion of one or more nucleotides into the sequence, addition of one or more nucleotides at either end of the sequence and deletion of one or more nucleotides at either end of or within the sequence.

When the first receptor is the PDGF receptor, the second receptor may suitably be the EGF receptor or vice versa. When the first receptor is the EGF receptor, the second receptor may also be the TGF (α or β) receptor, and vice versa. When the first receptor is the growth hormone receptor, the second receptor may suitably be the prolactin receptor or vice versa.

The DNA insert encoding the hybrid receptor may be prepared synthetically by established standard methods, e.g. the phosphoramidite method described by S.L. Beaucage and M.H. Caruthers, Tetrahedron Letters 22, 1981, pp. 1859-1869, or the method described by Matthes et al., EMBO Journal 3, 1984, pp. 801-805. According to the phosphoramidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.

The DNA insert may also be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the hybrid receptor polypeptide by hybridization using synthetic oligonucleotide probes in accordance with standard techniques (cf. Sambrook et al., Molecular Cloning: A Laboratory Manual,

2nd Ed., Cold Spring Harbor, 1989). In this case, a genomic or cDNA sequence encoding a part of either receptor may be modified at a site corresponding to the site(s) at which it is desired to introduce amino acid substitutions, e.g. by site-directed mutagenesis using synthetic oligonucleotides encoding the desired amino acid sequence for homologous recombination in accordance with well-known procedures.

Finally, the DNA insert may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA origin prepared by annealing fragments of synthetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various parts of the entire DNA insert, in accordance with standard techniques. The DNA insert may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202.

The hybrid DNA insert may be introduced into the cell by transfection of the cell with a recombinant expression vector comprising the insert. The expression vector may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

In the vector, the hybrid DNA insert should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription

of the DNA insert in mammalian cells are the SV 40 promoter (Subramani et al., Mol. Cell Biol. 1, 1981, pp. 854-864), the MT-1 (metallothionein gene) promoter (Palmiter et al., Science 222, 1983, pp. 809-814) or the adenovirus 2 major late promoter.

The DNA insert should also be operably connected to a suitable terminator, such as the human growth hormone terminator (Palmiter et al., op. cit.). The vector may further comprise elements such as polyadenylation signals (e.g. from SV 40 or
10 the adenovirus 5 Elb region), transcriptional enhancer sequences (e.g. the SV 40 enhancer) and translational enhancer sequences (e.g. the ones encoding adenovirus VA RNAs).

The recombinant expression vector may also comprise a DNA sequence enabling the vector to replicate in the host cell in
15 question. An examples of such a sequence is the SV 40 origin of replication. The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or one which confers resistance to a drug, e.g. neo-
20 mycin, hygromycin or methotrexate.

The procedures used to ligate the hybrid DNA insert with the DNA sequences coding for the promoter and the terminator, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well
25 known to persons skilled in the art (cf., for instance, Sambrook et al., op.cit.).

The cell of the present invention may suitably be used for the production of proteins of polypeptides of interest. Thus, the cell may further contain an inserted DNA sequence encoding a
30 desired polypeptide. Examples of such polypeptides are the human blood clotting factors IX, VIII or VII, human tissue-type plasminogen activator, human protein C, human plasminogen, etc.

Examples of suitable mammalian cells for transfection with expression vector containing the DNA insert described above are the COS (ATCC CRL 1650), BHK (ATCC CRL 1632, ATCC CCL 10) NIH/3T3 (ATCC CRL 1658) or CHO (ATCC CCL 61) cell lines.

5 Methods of transfecting mammalian cells and expressing DNA sequences introduced in the cells are described in e.g. Kaufman and Sharp, J. Mol. Biol. 159, 1982, pp. 601-621; Southern and Berg, J. Mol. Appl. Genet. 1, 1982, pp. 327-341; Loyter et al., Proc. Natl. Acad. Sci. USA 79, 1982, pp. 422-426; Wigler et

10 al., Cell 14, 1978, p. 725; Corsaro and Pearson, Somatic Cell Genetics 7, 1981, p. 603, Graham and van der Eb, Virology 52, 1973, p. 456; and Neumann et al., EMBO J. 1, 1982, pp. 841-845.

In another aspect, the present invention relates to a process

15 for producing a desired polypeptide, which comprises culturing a cell as described above in a suitable nutrient medium under conditions which are conducive to the expression of the polypeptide, and recovering the polypeptide from the culture. Although the medium used to culture the cells may be any

20 conventional medium suitable for growing mammalian cells, the cell of the invention has surprisingly been found to exhibit exceptionally favourable growth properties in serum-free medium which, as indicated above, is an advantage, i.a. because the purification of the desired polypeptide will be simplified, and

25 the yield of the polypeptide will be improved.

The polypeptide produced by the cells in this manner will often be secreted to the growth medium and may be recovered from the medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or

30 filtrate by means of a salt, e.g. ammonium sulphate, followed by purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, affinity chromatography, or the like.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is further described with reference to the drawings, wherein

Fig. 1A-1I shows the full-length cDNA sequence of the human 5 insulin receptor;

Fig. 2 shows the assembly into the α -subunit and part of the β -subunit of the IGF-I receptor (sIGF-I-R) of cDNA fragments generated by reverse transcription and PCR using specific oligonucleotide primers; the circled numerals refer to the 10 primers listed in Example 1;

Fig. 3A-3H shows the cDNA sequence of the soluble IGF-I receptor and the deduced amino acid sequence thereof, indicated in the conventional one-letter code;

Fig. 4A-4I shows the cDNA sequence of the extracellular domain 15 of a hybrid insulin/IGF-I receptor, wherein exons 2 and 3 of the insulin receptor have been replaced by exons 2 and 3 of the IGF-I receptor, and the deduced amino acid sequence thereof, indicated in the conventional one-letter code;

Fig. 5 is a graph showing the growth curves (day 3-7) of three 20 different cell lines, BHK, FCW 38-16 (BHK transfected with DNA encoding the hybrid insulin/IGF-I receptor according to Example 1) and hIR 12-14 (BHK transfected with DNA coding for the wild-type human insulin receptor), in medium containing 5% foetal calf serum;

25 Fig. 6 is a graph showing the growth curves (day 1-3) of three different cell lines, BHK, FCW 38-16 (BHK transfected with DNA encoding the hybrid insulin/IGF-I receptor according to Example 1) and hIR 12-14 (BHK transfected with DNA coding for the wild-

type human insulin receptor), in medium containing 5% foetal calf serum; and

Fig. 7 is a graph showing the growth curves (day 1-8) of three different cell lines, BHK, FCW 38-16 (BHK transfected with DNA encoding the hybrid insulin/IGF-I receptor according to Example 1) and hIR 12-14 (BHK transfected with DNA coding for the wild-type human insulin receptor), in serum-free medium supplemented with human insulin (BHK cells were also grown in serum-free medium without any added human insulin).

10 The invention is further illustrated in the following examples which are not in any way intended to limit the scope of the present invention.

EXAMPLE 1

Construction of cDNA encoding the human insulin receptor

15 Insulin receptor cDNA was isolated from a cDNA library generated from poly(A)⁺ mRNA isolated from the human lymphoblastoid cell line IM9 (available from the American Type Culture Collection, Rockville, Maryland, under the catalogue number ATCC CCL 159) stimulated with 1.4 µg/ml cortisol for 20 hours, substantially according to the method described by Okayama and Berg, Mol. Cell Biol. 2, 1982, p. 161 ff.; Okayama and Berg, Mol. Cell. Biol. 3(2), Feb. 1983, pp. 280-289; and Noma et al., Nature 319, 1986, p. 640 ff. An approximately 4000 bp clone containing the 3' end of the insulin receptor was
25 isolated. To obtain a full-length clone, primer extension was applied on mRNA from the IM9 cells using (10 µg total mRNA) AMV reverse transcriptase (60 U, available from Pharmacia LKB Biotechnology, Sweden) with 800 ng of the 3' oligonucleotide primer 5'-CATCTCAGCAAGATCTTGTC-3'. The second strand was
30 synthesized as described by Okayama and Berg, op. cit., using the 5' oligonucleotide 5'-ACCGGGAGCGCGCTCTGATC-3' as primer. The cDNA was digested with the restriction endonucleases BssHII

and BglII and ligated into an appropriate vector. A 1550 bp clone containing the 5' end of the insulin receptor was isolated. The full-length insulin receptor was assembled in the mammalian expression vector Zem219b (described in DK Patent 5 Application No. 3023/88) digested with NcoI and XbaI by ligating the 5' cDNA clone digested with NcoI and BglII and the 3' cDNA clone digested with SpaI and BglII. The DNA sequence of the full length insulin receptor cDNA is shown in Fig. 1A-1F.

Construction of cDNA encoding a soluble IGF-I receptor

10 A soluble IGF-I receptor cDNA was prepared from mRNA from human term placenta by a method involving polymerase chain reaction (PCR) using specific oligonucleotide primers (cf. R.K. Saiki et al., Science 239, 29 Jan., 1988, pp. 487-491, and US 4,683,202). mRNA was prepared by standard procedures as 15 described in Sambrook et al., op. cit. The mRNA was reverse transcribed into cDNA with AMV reverse transcriptase (Pharmacia LKB Biotechnology, Sweden) using the appropriate specific primers or an oligo-dT-primer at a final concentration of 800 ng/3.5 µg mRNA.

20 IGF-I receptor cDNA fragments were amplified by PCR using the Gene Amp kit (Perkin Elmer Cetus, Norwalk, CT, USA) as recommended by the manufacturer.

In each PCR, approximately 1µg of the reverse transcribed mRNA was used as template. The primers used for PCR all contained an 25 endonuclease restriction site permitting subcloning and assembly of the soluble IGF-I receptor. the following specific primers were used for PCR

1. 5'-CCA AAT AGG ATC CAT GAA CTC TGG CTC CGG AGG-3'
2. 3'-CCC GAA GTA GGC CTT AAG GTC GGT CTC GT-5'
- 30 3. 5'-TGG GCA GCT GCA GCG CGC CTG-3'
4. 3'-ATT GGA CCG TGG CCA TGG CCG-5'
5. 5'-TAA CCT GGC ACC GGT ACC GGC-3'

6. 3'-TCA AAG AGT TGC TTC GAA GAC-5'
7. 5'-AAC ACC ACG GCC GCA GAC ACC-3'
8. 3'-TGT CCT ATA CTT TTG ATT AGA TCT GAC TAG T-5'

The following restriction sites native to the IGF-I receptor 5 were part of the PCR primers: PstI, Asp718, XmaIII and HindIII. A BamHI site was incorporated in the primer 1 used to generate the 5' end of the receptor cDNA by introducing a mismatch in the sequence. The primer 8 used to generate the 3' end of the soluble IGF-I receptor cDNA was designed by introducing a mismatch in the sequence so as to include a termination codon in nucleotide position 2842-2844 followed by an XbaI site. Each PCR reaction cycle comprised denaturation of the template at 94°C for 1 minute, and annealing of the primers to the templates for 2 minutes at 50°C, followed by extension of 15 the primers for 3 minutes at 72°C. This cycle was repeated 25 times, resulting in specific IGF-I receptor fragments.

The isolated cDNA fragments were digested with the endonucleases BamHI and XbaI (New England Biolabs, MA, USA) and subcloned into the PBSII vector (Stratagene, CA, USA) by the 20 method described by Sambrook et al., op. cit. Cells of E. coli strain MC1061 (T.V. Huynk et al., in DNA Cloning, Vol. 1 (D.M. Glover, ed.), IRL Press Ltd., Oxford, England, 1983, pp. 56-110) and SCS-1 (D. Hanahan, J. Mol. Biol. 166, 1983, pp. 557-580) were made competent according to the method described by 25 D. Hanahan, in DNA Cloning, Vol. 1, supra, pp. 110-135, and used for transformation with the vectors indicated above. The soluble IGF-I receptor cDNA was assembled from four subcloned cDNA fragments as shown in Fig. 2 (BamHI-PstI, PstI-Asp718, Asp718-PstI, PstI-XbaI) according to the method described by 30 Sambrook et al., op. cit. The cDNA fragment(s) were sequenced by the enzymatic chain termination method described by F. Sanger et al., op. cit., using T4 DNA polymerase (Sequenase Kit, USB, Cleveland, Ohio, USA). The cDNA sequence of the soluble IGF-I receptor is shown in Fig. 3A-3E. The sequence was

identical to the published sequence (A. Ullrich et al., The EMBO Journal 5(10), 1986, pp. 2503-2512).

Construction of cDNA coding for a hybrid insulin-IGF-I receptor

cDNA coding for a hybrid receptor composed of the human insulin
5 receptor described above wherein the cDNA sequence coding for
exons 2 and 3 was replaced by the cDNA sequence coding for
exons 2 and 3 from the IGF-I receptor, was prepared by PCR as
described above. Primer 2 (shown above), which includes the
insulin receptor "compatible" restriction site EcoRI, was used
10 to generate an IGF-I receptor cDNA fragment corresponding to
the DNA sequence encoding exon 2 and 3 and the coding part of
exon 1 of the insulin receptor which was inserted into the
EcoRI site of the insulin receptor cDNA by the method described
by Sambrook et al., op. cit.. The sequence of the cDNA fragment
15 was established as described above, and the sequence of the
IGF-I receptor cDNA fragment inserted into the insulin receptor
was found to be identical with the published sequence (A.
Ullrich et al., op. cit.). The cDNA sequence of the hybrid
receptor is shown in Fig. 4A-4F.

20 The cDNA fragment encoding the hybrid insulin-IGF-I receptor
constructed as described above was inserted in the mammalian
expression vector Zem219b (described in DK Patent Application
No. 3023/88) which carries a gene conferring methotrexate
resistance to the host cell, and cDNA encoding the hybrid
25 receptor was transfected into BHK cells, resulting in the cell
line FCW 38-16. Resistant cells were selected with 0.4-2 μ M
methotrexate.

The hybrid receptor (sIGF-I-R.1-68) comprising an IGF-I
receptor in which the 68 N-terminal amino acids of the insulin
30 receptor α -subunit have replaced the equivalent IGF-I receptor
segment was constructed by means of restriction enzyme sites
similarly positioned in the two receptor cDNAs. The BamHI-XhoI
cDNA fragments were exchanged between the insulin receptor and

the IGF-I receptor resulting in sIGF-I-R.1-68. This hybrid cDNA was inserted into the mammalian expression vector pZem 219b and transfected into BHK cells, resulting in the cell line FCW 110.

During cultivation in 5% FCS, the cell line FCW 110 formed 5 grape-like clusters of loosely attached cells, forming many floating cells that stayed alive, indicating that this cell line may be adapted to grow in suspension with or without serum.

EXAMPLE 2

10 Growth performance of cells transfected with the hybrid insulin/IGF-I receptor

Materials and methods

Cell lines: BHK (Baby Hamster Kidney cells, Syrian Hamster)
FCW 38-16, according to Example 1,
HIR 12-14, BHK transfected with DNA coding
for the wild-type human insulin receptor.

Cells were grown in 1 μ M MTX (only the transformed cell lines), DMEM, 10% FCS, 1% PS, 1% Gln.

In a first experiment, 10^4 cells from each cell line were 20 divided among 25 different 5 cm culture dishes and grown in 5 % FCS on day 0. The cells were counted from 4 different plates every day. Two independent aliquots were sampled from each plate; where appropriate, floating or loosely attached cells were also counted in aspirated medium. Cells grown in this 25 growth curve experiment were propagated in standard medium for growing mammalian cells.

In a second experiment, 10^5 cells from each cell line were divided among 25 different 5 cm culture dishes on day 0. The medium was changed on day 1 to 0% FCS, but was supplemented

with 5 mg/l of human insulin. The cells were counted over the next days as described above.

Results

a) Growth in medium with 5% FCS

5 The growth curves for the three different cell lines in FCS-containing medium are shown in Fig. 5. Based on the counts from the first three days, the cell lines FCW 38-16 and hIR 12-14 show a doubling time of 9 hrs as opposed to 16 hrs for BHK cells.

10 This experiment was repeated the following week, but this time with additional cell counts on day 1 and 2. The growth curves corresponding to the cell counts are shown i Fig. 6.

When figures from the first two days are used to calculate the generation time, FCW 38-16 and hIR 12-14 double each 14.4 hr
15 and BHK doubles each 20.4 hr. All three cell lines had the same cell counts on day four, and were not counted further.

In the second week of experiment, all three cell lines had longer generation times; the ratio between the generation time for the transformed cell lines and BHK was 1.4 as compared to
20 1.7 for the first week.

b) Growth in serum-free medium supplemented with human insulin

Three growth experiments with all three cell lines in serum-free medium supplemented with human insulin were performed over three weeks, and cell counts from these three experiments were
25 averaged to generate the growth curves shown in Fig. 6.

~~BHK cells grown without serum and without added human insulin~~
were counted for one week.

FCW 38-16 consistently grew to higher densities under these conditions, but ultimately died on day 8 - 9.

hIR 12-14 formed grape-like clusters of loosely attached cells, forming many floating cells that stayed alive for 2 - 3 days.

5 Conclusion

In two independent growth-curve experiments in serum supplemented with 5% FCS, the transformed cell lines showed a shorter generation time than BHK cells. At the end of each experiment all three cell lines showed the same cell density on 10 the plates.

Although the generation times obtained in both weeks of analysis are not the same, it may be concluded that the growth curves support the observed difference in growth rate of FCW 38-16 (and hIR 12-14) compared to BHK.

15 Under serum-free conditions (supplemented with insulin), the FCW 38-16 cell line performed far better than both the BHK and hIR 12-14 cell lines, supporting the utility of cells of the present invention expressing a hybrid insulin/IGF-I receptor.

CLAIMS

1. A mammalian cell containing a hybrid DNA insert which comprises a first DNA sequence encoding part of the extracellular domain of a first cellular receptor and a second DNA
5 sequence encoding part of the extracellular domain of a second cellular receptor which is specific for a different ligand than the first cellular receptor.
2. A cell according to claim 1, wherein the first DNA sequence encodes an exon or a fragment thereof.
- 10 3. A cell according to claim 1, wherein the second DNA sequence encodes an exon or a fragment thereof.
4. A cell according to any of claims 1-3, wherein either the first or the second DNA sequence encodes a ligand-binding site of the first or second receptor.
- 15 5. A cell according to claim 1, wherein the DNA sequences coding for the first and second receptors exhibit a high degree of identity/homology in the organization and/or structure of the exons encoded by said sequences.
6. A cell according to any of claims 1-5, wherein a DNA
20 sequence encoding one or more exons, or a fragment thereof, of the extracellular domain of the first receptor is replaced by a DNA sequence encoding the corresponding exon or exons, or fragment thereof, of the extracellular domain of the second receptor.
- 25 7. A cell according to any of claims 1-5, wherein a DNA sequence encoding one or more exons, or a fragment thereof, of the extracellular domain of the second receptor is replaced by a DNA sequence encoding the corresponding exon or exons, or
30 fragment thereof, of the extracellular domain of the first receptor.

8. A cell according to any of claims 1-7, wherein the first receptor is the insulin receptor.
9. A cell according to any of claims 1-8, wherein the second receptor is the insulin-like growth factor (IGF) receptor.
- 5 10. A cell according to any of claims 1-7, wherein the first receptor is the platelet-derived growth factor (PDGF) receptor.
11. A cell according to claim 10, wherein the second receptor is the epidermal growth factor (EGF) receptor.
12. A cell according to any of claims 1-7, wherein the first
10 receptor is the EGF receptor.
13. A cell according to claim 12, wherein the second receptor is the transforming growth factor (TGF) receptor.
14. A cell according to any of claims 1-7, wherein the first receptor is the TGF receptor.
-
- 15 15. A cell according to claim 14, wherein the second receptor is the EGF receptor.
16. A cell according to any of claims 1-7, wherein the first receptor is a growth hormone receptor.
17. A cell according to claim 16, wherein the second receptor
20 is a prolactin receptor.
18. A cell according to any of claims 1-7, wherein the first receptor is a prolactin receptor.
19. A cell according to claim 18, wherein the second receptor is a growth hormone receptor.

20. A cell according to claim 8, wherein a DNA sequence encoding exon 2, or a fragment thereof, of the insulin receptor is replaced by a DNA sequence encoding exon 2, or a fragment thereof, of the IGF receptor.

5 21. A cell according to claim 8, wherein a DNA sequence encoding exon 3, or a fragment thereof, of the insulin receptor is replaced by a DNA sequence encoding exon 3, or a fragment thereof, of the IGF receptor.

22. A cell according to claim 8, wherein a DNA sequence
10 encoding exons 2 and 3, or a fragment thereof, of the insulin receptor is replaced by a DNA sequence encoding exons 2 and 3, or a fragment thereof, of the IGF receptor.

23. A cell according to claim 9, wherein a DNA sequence encoding exon 2, or a fragment thereof, of the IGF receptor is
15 replaced by a DNA sequence encoding exon 2, or a fragment thereof, of the insulin receptor.

24. A cell according to claim 9, wherein a DNA sequence encoding exon 3, or a fragment thereof, of the IGF receptor is replaced by a DNA sequence encoding exon 3, or a fragment
20 thereof, of the insulin receptor.

25. A cell according to claim 9, wherein a DNA sequence encoding exons 2 and 3, or a fragment thereof, of the IGF receptor is replaced by a DNA sequence encoding exons 2 and 3, or a fragment thereof, of the insulin receptor.

25 26. A cell according to claim 22, wherein the DNA insert has the partial DNA sequence shown in Fig. 4A-4F (encoding the extracellular domain of the hybrid insulin/IGF-I receptor), or a suitable modification thereof.

27. A cell according to any of claims 1-26, which further contains an inserted DNA sequence encoding a desired polypeptide.

28. A process for producing a desired polypeptide, which 5 comprises culturing a cell according to claim 27 in a suitable nutrient medium under conditions conducive to the expression of the polypeptide and recovering the polypeptide from the culture.

29. A process according to claim 28, wherein the medium is a 10 serum-free medium.

1/30

1 ACGGGAGCGCGCTCTGATCCGAGGAGACCCCGGCTCCCGCAGCCATGGGCACCGGG 60
-----+-----+-----+-----+-----+
TGCCCTCGCGCGGAGACTAGGCTCCTCTGGGGCGGAGGGCGTGGTACCCGTGGCCC
61 GGCCGGGGGGGGCGCGCGCGCGCTGCTGTGTGGCGGTGGCCGCGCTGCTACTGGGC 120
-----+-----+-----+-----+-----+
CCGGCCGCCCGCGCGCGGGCGGCGGACGACACCGCCACCGCGCGCAGATGACCCG
121 GCCGGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGCATGGATATCCGGAAACCTC 180
-----+-----+-----+-----+-----+
CGCGCCCGGTGGACATGGGGCTCTCCACACAGGGCCGTACCTATAGGCCCTGTTGGAG
181 ACTAGTTGCATGAGCTGGAGAATTGCTCTGTCTATCGAAGGACACTTGCAGATACTCTTG 240
-----+-----+-----+-----+-----+
TGATCCAAACGTACTCGACCTCTTAACGAGACAGTAGCTTCTGTGAACGTCTATGAGAAC
241 ATGTTCAAAACGAGGCCCGAAGATTTCGAGACCTCAGTTTCCCAAACTCATCATGATC 300
-----+-----+-----+-----+-----+
TACAAGTTTGTCTCCGGCTTCTAAAGGCTCTGGAGTCAAAGGGTTTGTAGTAGTACTAG
301 ACTGATTACTTGTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAGGACCTGTTCCCC 360
-----+-----+-----+-----+-----+
TGACTAATGAACGACGAGAGGCCAGATACCCGAGCTCTCGGACTTCTTGGACAAGGGG
361 AACCTCACGGTCAATCCGGGGATCACGACTGTTCTTTAACTACGCGCTGGTCACTCTCGAG 420
-----+-----+-----+-----+-----+
TTGGAGTGCCAGTAGGCCCTAGTGCTGACAAGAAATTGATGCGCGACCAAGTAGAGCTC
421 ATGGTTCACTCAAGGAACCTCGGCCCTCTACAACCTGATGAACATCACCCGGGTTCTGTC 480
-----+-----+-----+-----+-----+
TACCAAGTGGAGTTCTTGAGCCGGAGATGTTGGACTACTTGTAGTGGGCCCCAAGACAG
481 CGCATCGAGAAGAAACAATGAGCTCTGTTACTTGGCCACTATCGACTGGTCCCGTATCCTG 540
-----+-----+-----+-----+-----+
CCGTAGCTCTTCTTGTACTCGAGACAAATGAACCGGTGATAGTGAACAGGGCATAGGAC
541 GATTCCGTGGAGGATAATTACATCGTGTGTTGAACAAAGATGACAACGAGGAGTGTGGAGAC 600
-----+-----+-----+-----+-----+
CTAAGGCACCTCCTATTAAATGTAGCACAACTTGTCTTACTGTTGCTCCTCACACCTCTG

Fig. 1a

2/30

```

601  ATCTGTCCGGGTACCGGAAGGGCAAGACCAACTGCCCCCGCACCGTCAATCAACGGGCAG
      +-----+-----+-----+-----+-----+-----+
      TAGACAGGCCCATGGCGCTTCCCGTTCTGGTTGACGGGGCGGTGGCAGTAGTTGCCCGTC
      660

661  TTTGTGAAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGGCCGACCATCTGTAAG
      +-----+-----+-----+-----+-----+-----+
      AAACAGCTTGCTACAACCTGAGTATCAGTGACGGTCTTTCAAACGGGCTGGTAGACATTC
      720

721  TCACACGGCTGCACCGCCGAAGGCCCTCTGTTGCCACAGCGAGTGCCCTGGGCAACTGTTCT
      +-----+-----+-----+-----+-----+-----+
      AGTGTCCGACGTTGGCGGCTTCCGGAGACAACGGTGTGCTCACGGACCCGTTGACAAGA
      780

781  CAGCCCGACGACCCCAACCAAGTGCGTGGCCTGCCGCAACTTCTACCTGGACGGCAGGTGT
      +-----+-----+-----+-----+-----+-----+
      GTCGGGCTGCTGGGGTGGTTCA CGCACCGGACGGCGTTGAAGATGGACCTGCCGTCACACA
      840

841  GTGGAGACCTGCCCGCCCGCTACTACCACCTTCCAGGACTGGCGCTGTGTGAACCTTCAGC
      +-----+-----+-----+-----+-----+-----+
      CACCTCTGGACGGCGGGGGCA TGA TGGTGAAGGTCTGACCCGGACACACTTGAAGTCG
      900

901  TTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGCTGCCACCAGTAC
      +-----+-----+-----+-----+-----+-----+
      AAGACGGTCTGGACGTGGTGTTTACGTTCTTGAAGCGCCTCCGTCCCGACGGTGGTCATG
      960

961  GTCATTCAACAACAAGTGCA TCCCTGAGTGTCCCTCCGSGTACACGATGAATTCAGC
      +-----+-----+-----+-----+-----+-----+
      CAGTAAGTGTGTTGTTCA CGTAGGGACTCACAGGAGGCCCATGTGCTACTTAAGGTCTG
      1020

1021  AACTTGTGTGACCCCATGCCCTGGGTCCCTGTCCCAAGGTGTGCCACCTCCTAGAAAGGC
      +-----+-----+-----+-----+-----+-----+
      TTGAACGACACGTGGGTACGGACCCAGGACAGGGTTCCACACGGTGGAGGATCTTCCG
      1080

1081  GAGAAGACCATCGACTCGGTGACGTCTGCCCCAGGAGCTCCGAGGATGCACCCGTCATCAAC
      +-----+-----+-----+-----+-----+-----+
      CTCTTCTGGTAGCTGAGCCACTGCAGACGGGTCTTCGAGGCTCCTACGTGGCAGTAGTTG
      1140

1141  GGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAGCTAGAAGCCAAAC
      +-----+-----+-----+-----+-----+-----+
      CCTCAGACTAGTAGTTGTAAGCTCCTCCGTTGTTAGACCGTCGACTCGATCTTCGGTTG
      1200

```

Fig. 1b

4/30

1801 CCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACTTTTCGGATGAACGCCGG
GGACCTGGGTCTATACGGTAGAACAACATTCTGGGACCACTGGAAGCCCTACTTGGCGCC 1860
1861 ACCTATGGGGCCAAAGAGTGACATCTTATGTCTCCAGACAGATGCCACCAACCCCTCTGTG
TGGATACCCCGGTTCTCACTGTAGTAATAACAGGTCTGTCTACGGTGGTTGGGGAGACAC 1920
1921 CCCTTGATCCCAATCTCAGTGTCTAACTCATCTCCAGATTATCTGAAGTGGAACCA
GGGACCTAGGTTAGAGTCAAGATGAGTAGTAGGGTCTAATAAGACTTCACTTTGGT 1980
1981 CCCTCCGACCCCAATGGCAACATCACCCACTACTGGTTTCTGGGAGAGCGCGGAA
GGAGGCTGGGTTACCGTTGTAGTGGGTGATGGACCAAAAGACCCCTCTCCGTCCGCCTT 2040
2041 GACAGTGAGCTGTTTCGAGCTGGATTATTGGCTCAAAGGGCTGAAGCTGCCCTCGAGGACC
CTGTCACTCGACAAGCTCGACCTAATAACGGAGTTTCCCGACTTCGACGGGAGCTCCTGG 2100
2101 TGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAGCACAACCAAGAGTGAGTATGAGGAT
ACCAGAGGTGGTAAGCTCAGACTTCTAAGAGTCTTCGGTGGTCTCACTCATCTCCTA 2160
2161 TCGGCCGGCGAATGCTCTCTCTCCAAAGACAGACTCTCAGATCCTGAAGGAGCTGGAG
AGCCGGCCGCTTACGACGAGGACAGGTTTCTGTCTGAGAGTCTAGGACTTCTCTGACCTC 2220
2221 GAGTCTCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTTGTTTCGTCCCCAGG
CTCAGGAGCAAAATCCTTCTGCAAACTCCTAATGGAAGTGTGACCAAAAGCAGGGGTCC 2280
2281 CCATCTCGGAAACGAGGTCCTTGGCGATGTTGGGAATGTGACGGTGGCGGTGCCACG
GGTAGAGCCTTTGGGTCAGGGAAACGCTACAACCTTACACTGCCACCGGCACGGGTGC 2340

Fig. 1d

5/30

2341 GTGGCAGCTTTCCCCAAACACTTCCTCGACCAGCGTGGCCACGAGTCCGGAGGAGCACAGG 2400
-----+-----+-----+-----+-----+-----+
CACCGTCGAAAGGGGTTGTGAAGGAGCTGGTCGCACGGGTGCTCAGGCCCTCCTCGTGTCC
2401 CCTTTTGAGAAAGGTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGGGACACTTCACG 2460
-----+-----+-----+-----+-----+-----+
GGAAAACTCTTCCACCACTTGTTCCTCAGCGACCAAGTAGAGGCCGAACGGTGTGAAGTGC
2461 GGCTATCGCATCGAGTCGAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTG 2520
-----+-----+-----+-----+-----+-----+
CCGATAGCGTAGCTCGACGTCGGAACGTTGGTCTGTGGGGACTCCTTGCCACGTCACAC
2521 GCAGCCTACGTCAGTGGGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCT 2580
-----+-----+-----+-----+-----+-----+
CGTCGGATGCAGTCACGCTCCTGGTACGGACTTCGGTTCGGACTACTGTAA CAACCGGGA
2581 GTGACCGCATGAAATCTTTGAGAAACAACGTCGTCCTCACTTGATGTGGCAGGAGCCGAAGGAG 2640
-----+-----+-----+-----+-----+-----+
CACTGCGTACTTTAGAAACTCTTGTTCAGCAGGTGAAC TACACCCGTCCTCGGCTTCCTC
2641 CCCAATGGTCTGATCGTGTGATGAAGTGAGTTATCGGCGATATGATGATGAGGAGCTG 2700
-----+-----+-----+-----+-----+-----+
GGGTTACCAGACTAGCACGACATATCTCACTCAATAGCCGCTATACCACTACTCCTCGAC
2701 CATCTCTCGGACACCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTCGGTGGGCTG 2760
-----+-----+-----+-----+-----+-----+
GTAGAGACGCTGTGGGCGTTCTGTGAAGCGAGACCTTGCCCCGACGTC CGACGCCCGAC
2761 TCACCGGGGAAC TACAGCGTGCGAATCCGGGGCCACCTCCCTTGCGGGCAACGGCTCTTGG 2820
-----+-----+-----+-----+-----+-----+
AGTGGCCCCCTTGATGTCCGACCGCTTAGGCCCCGGTGGAGGGAA CGCCCGTTGCCGAGAACC

Fig. 1e

6/30

2821 ACGGAACCCACCTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAAATATTGCAAAA
+-----+-----+-----+-----+-----+-----+
TGCCTTGGGTGATAAAGATGCACTGTCTGATAAATCTGCAGGGCAGTTTATAACGTTTTT
2880
2881 ATTATCATCGGCCCCCTCATCTTTGTCTTTCTCTTCAAGTGTGTGATGGGAAGTATTAT
+-----+-----+-----+-----+-----+-----+
TAATAGTAGCCGGGGAGTAGAACAAGAGAGAAAGTCAACAACAATAACCTTCATAAATA
2940
2941 CTATTCTGAGAAAGAGGCAGCCAGATGGCCCGCTGGGACCGCTTTACGCTTCTTCAAAC
+-----+-----+-----+-----+-----+-----+
GATAAGGACTCTTTCTCCGTCGGTCTACCCGGCGACCTGGCGAAATGCGAAGAGTTTG
3000
3001 CCTGAGTATCTCAGTGCAGTGATGTGTTTCCATGCTCTGTGTACGTCGCCGGACGAGTGG
+-----+-----+-----+-----+-----+-----+
GGACTCATAGAGTCACGGTCACTACACAAGGTAGAGAGACACATGCACGGCCTGCTCACC
3060
3061 GAGGTGCTCGAGAGAAGATCACCCCTCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATG
+-----+-----+-----+-----+-----+-----+
CTCCACAGAGCTCTTCTAGTGGGAGGAAGCTCTCGACCCCGTCCCGAGGAAGCCGTAC
3120
3121 GTGTATGAGGGCAATGCCAGGGACATCATCAAGGTGAGGCAGAGACCCCGGTGCGGTG
+-----+-----+-----+-----+-----+-----+
CACATACTCCCGTTACGGTCCCTGTAGTAGTTCCCACTCCGTCTCTGGGCGCACCCGCCAC
3180
3181 AAGACGGTCAACGAGTCAGCCAGTCTCCGAGAGCGGATTTGAGTTCTCAATGAGGCCCTCG
+-----+-----+-----+-----+-----+-----+
TTCTGCCAGTTGCTCAGTCGGTCAAGAGGCTCTCGCCTAACTCAAGGAGTTACTCCGGAGC
3240
3241 GTCATGAAGGGCTTCACCTGCCATCAAGTGGTGGCCCTCTGGGAGTGGTGTCCAAGGGC
+-----+-----+-----+-----+-----+-----+
CAGTACTTCCCGAAGTGGACGGTAGTGCAACACCGGGAGGACCCCTCACCCACAGGTTCCCG
3300
3301 CAGCCCACGCTGGTGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGT
+-----+-----+-----+-----+-----+-----+
GTCGGGTGCGACCACTACCTCGACTACCGAGTGCCTCTGGACTTCTCGATGGAGGCA
3360
3361 TCTCTGCGGCCAGAGGCTGAGATAAATCTGGCCGCCCTCCCCCTACCCCTTCAAGAGATG
+-----+-----+-----+-----+-----+-----+
AGACACGCCCGGTCTCCGACTCTTATTAGGACCGGGGGAGGGGATGGGAAGTTCTCTAC
3420

Fig. 1f

7/30

3421 ATTCAGATGGCGGCAGAGATTGCTGACGGGATGGCCCTACCTGAACGCCAAGAAAGTTTGTG 3480
-----+-----+-----+-----+-----+-----+-----+
TAAGTCTACCGCGCTCTAAGCACTGCCCTACCGGATGGACTTGGGTTCTTCAAACAC
3481 CATCGGGACCTGGCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGA 3540
-----+-----+-----+-----+-----+-----+-----+
GTAGCCCTGGACCGTCGCTCTTTGACGTACCAGCGGGTACTAAATGACAGTTTTTAACCT
3541 GACTTTGGAATGACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGT 3600
-----+-----+-----+-----+-----+-----+-----+
CTGAAACCTTACTGGTCTCTGTAGATACTTTGGCTTAAATGATGGCCTTTCCCGCGTTCCCA
3601 CTGCTCCCCTGTACGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTTCACCACCTTCT 3660
-----+-----+-----+-----+-----+-----+-----+
GACGAGGGACATGCCACCTACCGTGGCCTCAGGGACTTCCCTACCCAGAAAGTGGTGAAGA
3661 TCTGACATGTGGTCCTTTGGCGTGGTCTTTGGGAAATCACCAAGCTTGGCAGAACAGCCT 3720
-----+-----+-----+-----+-----+-----+-----+
AGACTGTACACCAGGAACCGCACAGGAAACCTTTAGTGGTGAACCGTCTTGTGCGGA
3721 TACCAAGGCCCTGTCTAATGAACAGGTGTTGAAATTTGTTCATGGATGGAGGGTATCTGGAT 3780
-----+-----+-----+-----+-----+-----+-----+
ATGGTTCCGGACAGATTACTTGTGCCACAACCTTTAAACAGTACCTACCTCCCATAGACCTA
3781 CAACCCGACAACTGTCCAGAGAGAGTCACTGACCTCATGCCGATGTGCTGGCAATTCAAC 3840
-----+-----+-----+-----+-----+-----+-----+
GTTGGGCTGTTGACAGGTCTCTCTCAGTGACTGGAGTACCGGTACACGACCGTTAAGTTG
3841 CCCAACATGAGGCCAACCTTCCCTGGAGATTGTCAACCTGTCAAGGACGACCTGCACCCC 3900
-----+-----+-----+-----+-----+-----+-----+
GGGTTGTACTCCGGTTGGAAGGACCTCTAACAGTTGGACGAGTTCTCTGCTGGACGTGGGG
3901 AGCTTTCAGAGAGGTGTCGTTCTTCCACAGCGAGGAGAAACAAAGGCTCCCGAGAGTGAGGAG 3960
-----+-----+-----+-----+-----+-----+-----+
TCGAAAGGTCTCCACAGCAAGAAGGTGTGCGCTCCTCTTGTTCGAGGGCTCTCACTCCTC
3961 CTGGAGATGGAGTTTGAGGACATGGAGAAATGTGCCCCCTGGACCGTTCTTCGCACTGTGAG 4020
-----+-----+-----+-----+-----+-----+-----+
GACCTCTACCTCAAACTCCTGTACCTCTTACACGGGGACCTGGCAAGGAGCGTGACAGTC

Fig. 1g

8/30

4021 AGGAGGAGGGGGGGGGGATGGAGGGTCTCGCTGGGTTTCAAGCGGAGCTACGAG
-----+-----+-----+-----+-----+
TCCCTCCTCGCCCCCGCCCTACCTCCAGGAGCGACCAAGTTCGCTCGATGCTC 4080

4081 GAACACATCCCTTACACACACATGAACGGAGGCAAGAAACGGGGGATTTGACCTTG
-----+-----+-----+-----+-----+
CTTGTAAGGAATGTGTGTGTA CTGCTCCGTTCTTTTGGCCCGCTAAGACTGGAAC 4140

4141 CCTCGGTCCAATCCTTCCTAACAGTGCCTACCGTGGGGGGGGGAGGGTTCCTCATT
-----+-----+-----+-----+-----+
GGAGCCAGGTAGGAAGGATGTCAACGGATGGCACCGCCCCCGCCCGTCCCAAGGGTAA 4200

4201 TTCGCTTTCCTCTGGTTTGAAAGCCTCTGGAACCTCAGGATTTCTCAGACTCTACCATG
-----+-----+-----+-----+-----+
AAGCGAAAGGAGACCAAACTTTTCGGAGACCTTTTGAGTCTTAAGAGTGTGAGATGGTAC 4260

4261 TCCAATGGAGTTCAGAGATCGTTCTCTATACATTTCTGTTCACTTTAAGGTGGACTCGTTT
-----+-----+-----+-----+-----+
AGGTTACCTCAAGTCTTAGCAAGGATATGTAAAGACAAGTAGAATTTCCACCTGAGCAAA 4320

4321 GGTACCAATTTAACTAGTCTCTGAGAGGATTTAACTGTGAACCTGGAGGGCAAGGGGT
-----+-----+-----+-----+-----+
CCAAATGGTTAAATTGATCAGGACGTCTCCTAAATTGACACTTGGACCTCCCGTTCCCCAA 4380

4381 TCCACAGTTGCTGCTCCTTTGGGGCAACGACGGTTTCAAAACAGGATTTGTGTTTTTC
-----+-----+-----+-----+-----+
AGGTGTCAACGACGAGGAAACCCCGTTGCTGCCAAAGTTTGGTCTTAAACACAAAAAAG 4440

4441 GTTCCCCCCCCCCCCAGCAGATGGAAGAAAGCACCTGTTTTTACAAATCTTTTT
-----+-----+-----+-----+-----+
CAAGGGGGTGGCGGGGTCGTCTACCTTTCTTCTGCGACAAAAATGTTAAGAAAAA 4500

4501 TTTTTTTTTTTTTTGTGCTGGTGTCTGAGCTTCAGTATAAAAGACAAAACTTCCTGTTG
-----+-----+-----+-----+-----+
AAAAAAAACAAAAAACGACCAACAGACTCGAAGTCATATTTCTGTTTTTGAAGGACAAAC 4560

4561 TGGACAAAAGTTCGAAAGAAAAACAAAAACAAACACCCAGCCCTGTTCCAGGAGAAAT
-----+-----+-----+-----+-----+
ACCTTGTTTTCAAGCTTTCTTTTTTTGTTTTTGTGGTCCGGGACAAAGGTCTCTTA 4620

Fig. 1h

9/30

4621 TTCAAGTTTTACAGGTTGAGCTTCAAGATGGTTTTTTTTGGTTTTTTTTTTTTTCTCTCATC
-----+-----+-----+-----+-----+-----+
AAGTTCAAAATGTCCAACCTCGAAGTTCTACCAAAAAAACCAAAAAAAGAGAGTAG
4681 CAGGCTGAAGGATTTTTTTTTCTTTACAAAATGAGTTCCTCAAATTGACCAATAGCTGC
-----+-----+-----+-----+-----+-----+
GTCCGACTTCTTAAAAAAGAAATGTTTACTCAAGGAGTTTAACGGTTATCGACG
4741 TGCTTTCATATTTGGATAAGGGTCTGTGGTCCCGCGTGTGCTCACGTGTGTATGCACG
-----+-----+-----+-----+-----+-----+
ACGAAAGTATAAAACCTATTCCAGACACACCGGGCCGACACGAGTGACACATACGTGC
4801 TGTGTGTGTCATTAGACACGGCTGACGTGTGTGCAAAAGTATCCATGCGGAGTTGATGCT
-----+-----+-----+-----+-----+-----+
ACACACACAGGTAATCTGTGCCGACTGCACACACAGTTTCATAGGTACGCCCTCAACTACGA
4861 TTGGGAATTGGCTCATGAAGGTTCTTCTCAAGGGTGCAGAGCTCATCCCCCTCTCTCTTC
-----+-----+-----+-----+-----+-----+
AACCCTTAACCGAGTACTTCCAAGAAGAGTTCCCAACGCTCGAGTAGGGGAGAGAGGAAG
4921 CTCTTATTGACTGGGAGACTGTGCTCTCGACAGATTCTTCTGTGTCAGAAAGTCTAGCC
-----+-----+-----+-----+-----+-----+
GAAGAAATAACTGACCCCTCTGACACGAGAGCTGTCTAAGAAGAACACAGTCTTCAGATCGG
4981 TCAGGTTTCTACCCCTCCCTTCACATTGGTGGCCCAAGGGAGGAGCATTTTCATTGGAGTGA
-----+-----+-----+-----+-----+-----+
AGTCCAAAGATGGGAGGGAAGTGTAAACACCGGTTCCCTCCTCGTAAAGTAAACCTCACT
5041 TTATGAATCTTTTCAAGACCAACCAAGCTTAGGACATTAAAAAAGAAAAAAGAAAAAGA
-----+-----+-----+-----+-----+-----+
AATACCTAGAAAAAGTTCTGGTTTGGTTCGATCCTGTAAATTTTTTTTTTTCTTTTTTCT
5101 AAGAAAAACAAAATCGAAAAAGGAAAAAAGAAAAAAGAACTGAGATGACAGAGTTTGAGA
-----+-----+-----+-----+-----+-----+
TTCTTTTTTGTGTTTACCTTTTTCCTTTTTTTTTTTTCTTGACTCTACTGTCTCAAAACTCT
5161 ATATATTTGTACCATATTT
-----+-----+-----+-----+-----+-----+
TATATAAACATGGTATAAA

Fig. 1i

10/30




Fig. 2

11/30

B a m H I
 165 GGATCCATGAAGTCTGGCTCCGAGGAGGGTCCCGACCTCGCTGTGGGGCTCCTGTTT 224
 CTTAGGTACTTCAGACCGAGGCCTCTCCAGGGGCTGGAGCGACACCCCGAGGACAAA
 G S M K S G S G G S P T S L W G L L F -
 225 CTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGGGGCCAGGCATCGAC 284
 GAGAGCGCGCGAGAGCGGCTGCTCACCTCTTTAGACGCCCGGTCCGCTAGCTG
 L S A A L S L W P T S G E I C G P G I D -
 285 ATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTAC 344
 TAGGCGTTGCTGATAGTCGTGACTTCGGGACCTTTGACGTGCCACTAGCTCCCGATG
 I R N D Y Q Q L K R L E N C T V I E G Y -
 345 CTCCACATCCTGCTCATCTCCAAGCCGAGGACTACCGCAGCTACCGCTTCCCAAGCTC 404
 GAGGTGTAGGACGAGTAGAGGTTCCGGCTCCTGATGGCGTCGATGGCGAAGGGGTTCCGAG
 L H I L L I S K A E D Y R S Y R F P K L -
 405 ACGGTCATTACCGAGTACTTGCTGTGTTCCGAGTGGCTGGCTCGAGAGCCCTCGGAGAC 464
 TGCCAGTAATGGCTCATGAACGACGACAAGGCTCACCGACCGGAGCTCTCGAGGCCCTCTG
 T V I T E Y L L L F R V A G L E S L G D -
 465 CTCTTCCCCAACCTCACGGTCATCCCGGGCTGGAAACTTCTACAACCTACGCCCTGGTC 524
 GAGAAGGGGTTGGAGTGCCAGTAGCGGCCGACCTTTGAGAAGATGTTGATGCGGGACCAG
 L F P N L T V I R G W K L F Y N Y A L V -

Fig. 3a

12/30

525 ATCTTCGAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGG 584
TAGAAGCTCTACTGGTTAGAGTTCCTATAACCCGAAATGTTGGACTCCTTGTAAATGAGCC
I F E M T N L K D I G L Y N L R N I T R -
585 GGGGCCATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCC 644
CCCCGGTAGTCCTAACCTCTTTTACGACTGGAGACAATGGAGAGGTGACACCTGACCAGG
G A I R I E K N A D L C Y L S T V D W S -
645 CTGATCCTCGGATGCGGTGTCCCAATAACTACATTGTGGGGAATAAGCCCCCAAGGAATGT 704
GACTAGGACCTACGCCACAGGTTATTGATGTAAACACCCCTTATTTCGGGGGTTTCCTTACA
L I L D A V S N N Y I V G N K P P K E C -
705 GGGGACCTGTGTCCAGGGACCATGGAGGAGAGCCGATGTGTGAGAAGACCACCATCAAC 764
CCCCTGGACACAGGTCCTCGGTACCTCCTCTTCGGCTACACACTCTTCTGGTGGTAGTTG
G D L C P G T M E E K P M C E K T T I N -
765 AATGAGTACAACCTACCGCTGCTGGACCAACACCGCTGCCAGAAAATGTGCCCAAGCACG 824
TACTCATGTTGATGGCGACGACCTGCTGTTGGCGACGGTCTTTTACACGGGTTCTGTC
N E Y N Y R C W T T N R C Q K M C P S T -
825 TGTGGGAAGCGGGGTGCACCGAGAACAAATGATGCTGCCACCCCGAGTGCCTGGGCAGC 884
ACACCCCTTCGCCCCGCACGTGGCTCTTGTACTCAGACGGTGGGGCTCAGGACCCGTCG
C G K R A C T E N N E C C H P E C L G S -

Fig. 3b

13/30

885 TGCAGCGCGCTGACAAACGACACGGCTGTGTAGCTTGGCCGCACTACTACTATGCCGGT 944
ACGTCGCGCGGACTGTTGCTGTGCGCGACACATCGAACGGCGGTGATGATGATACGGCCA
C S A P D N D T A C V A C R H Y Y A G -
945 GTCTGTGTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGAC 1004
CAGACACACGGACGGACGGCGGGTGTGGATGTCCAACTCCCGACCGCGACACACCTG
V C V P A C P P N T Y R F E G W R C V D -
1005 CGTGACTTCTGCCCAACATCCTCAGCGCCGAGAGCAGCACTCCGAGGGGTTGTGATC 1064
GCACTGAAGACGCGGTTGTAGGAGTCGCGGCTCTCGTCGTGAGGCTCCCAAAACACTAG
R D F C A N I L S A E S S D S E G F V I -
1065 CACGACGGCGAGTGCAATGACGAGTGCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGC 1124
GTGCTGCCGCTCACGTACGTCCTACGGGGAGCCCGAAGTAGGCGTTGCCGTCGGTCTCG
H D G E C M Q E C P S G F I R N G S Q S -
1125 ATGTAAGTATCCCTTGTGAAGTCTTGGCCGAGGCTGTGAGGAGAAAGAAACA 1184
TACATGACGTAGGGAACACTTCCAGGAACGGGCTTCCAGACACTCCTTTCTTTTGT
M Y C I P C E G P C P K V C E E K K T -
1185 AAGACCATGATTCGTGTTACTTCTCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGC 1244
TTCTGGTAACTAAGACAATGAAGACGAGTCTACGAGGTTCTACGTGGTAGAAGTTCCCG
K T I D S V T S A Q M L Q G C T I F K G -
1245 AATTGCTCATTAACATCCGACGGGGGAATAACATGCTTCAGAGCTGGAGAACTTCATG 1304
TTAAACGAGTAATTGTAGGCTGCCCCCTTATTGTAACGAAGTCTCGACCTCTTGAAGTAC
N L L I N I R R G N N I A S E L E N F M -

Fig. 3c

15/30

1725 GATCTCATCAGCTTCAACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTAT 1784
CTAGAGTAGTCGAAGTGGCAAAATGATGTTCTTCGTGGGAAATTTCTACAGTGTCTCATA
D L I S F T V Y Y K E A P F K N V T E Y -
1785 GATGGCAGGATGCCCTGGGCTCCAAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCC 1844
CTACCCGTCTTACGGACGCCGAGGTTGTTCGACCTTGTACCCACCTGCACCTGGAGGGCGGG
D G Q D A C G S N S W N M V D V D L P P -
1845 AACAGGACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCC 1904
TTGTTCCCTGCACCTCGGGCCGTAGAAATGATGTACCCGACTTCGGGACCTGAGTCATGCGG
N K D V E P G I L L H G L K P W T Q Y A -
1905 GTTACGTCAAGCGTGTGACCCCTCAACATGGTGGAGAACGACCATATCCGTGGGGCCAAAG 1964
CAAATGCAGTCCGACACTGGGAGTGGTACCACCTCTTGTGTATAGGCACCCCGGTTTC
V Y V K A V T L T M V E N D H I R G A K -
1965 AGTGAGATCTTGATACATTCGCACCAATGCTTCAGTTCTTCCATTCCTTGGACGTTCTT 2024
TCACTCTAGAACATGTAAGCGTGGTTACGAAGTCAAGGAAGTAAGGGAACCTTGCAAGAA
S E I L Y I R T N A S V P S I P L D V L -
2025 TCAGCATCGAACTCCTCTTCTCAGTTAATCGTGAAGTGAACCCCTCCCTCTCTGCCCAAC 2084
AGTCGTAGCTTGAGGAGAAGAGTCAATTAGCACCTTCACCTTGGGAGGGAGACGGGTTG
S A S N S S S Q L I V K W N P P S L P N -

Fig. 3e

16/30

2085 GGC AACCTGAGTTACTACATTGTGGCTGGCAGCGGAGCCTCAGGACGGCTACCTTTAC 2144
CCGTTGGACTCAATGATGTAACACCGACCGTCGCGCTCGGAGTCCTGCGCATGGAATG
G N L S Y Y I V R W Q R Q P Q D G Y L Y -
2145 CGGCACAATTACTGCTCCAAAGACAAATCCCCATCAGGAAGTATGCCGACGGCACCATC 2204
GCCGTGTTAATGACGAGGTTCTGTTTAGGGGTAGTCTTCATACGGCTGCCGTGGTAG
R H N Y C S K D K I P I R K Y A D G T I -
2205 GACATTGAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGAGAAAGGCCT 2264
CTGTAACTCCTCCAGTGCTCTTGGGGTCTCTGACTCCACACACCCCTCTTTCCCGGA
D I E E V T E N P K T E V C G G E K G P -
2265 TGCTGGCCTGCCCCAAACTGAAGCCGAGAGCAGGCCGAGAGGAGGAGGCTGAATAC 2324
ACGACGGGACGGGGTTTGTGACTTCGGCTCTTCGTCGGGCTCTTCTCCTCCGACTTATG
C C A C P K T E A E K Q A E K E E A E Y -
2325 CGCAAAGTCTTTGAGAAATTTCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAG 2384
GCGTTTCAGAAACTCTTAAAGGACGTGTTGAGGTAGAAGCACGGGTCTGGACTTTTCTCTC
R K V F E N F L H N S I F V P R P E R K -
2385 CGGAGAGATGTCATGCAAGTGGCCCAACACCACCATGTCCAGCCGAGGAGGAAACACCCAG 2444
GCCTCTCTACAGTACGTTCAACCCGGTTGTGGTGGTACAGGTCCGCTTCGCTCTGTGGTGC
R R D V M Q V A N T T M S S R S R N T T -

Fig. 3f

17/30

2445 GCGCAGACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTCTTT
CGCGTCTGTGGATGTTGTAGTGGCTGGGCCCTCTCGACCTCTGTCTCATGGGAAAGAAA
2504
A A D T Y N I T D P E E L E T E Y P F F -
2505 GAGAGCAGAGTGGATAACAAGGAGAGAACTGTCAATTTCTAACCTTCGGCCCTTTCACATTG
CTCTCGTCTCACCTATTGTTCTCTCTTGACAGTAAGATTGGAAGCCGGAAGTGTAAAC
2564
E S R V D N K E R T V I S N L R P F T L -
2565 TACCGCATCGATATCCACAGCTGCAACACGAGGCTGAGAAAGCTGGGCTGCAGCGCCTCC
ATGGCGTAGCTATAGGTGTCGACGTTGGTGCTCCGACTCTTCGACCCGACGTCGCGGAGG
2624
Y R I D I H S C N H E A E K L G C S A S -
2625 AACTTCGTCTTTGCAAGGACTATGCCCGCAGAGGAGCAGATGACATTCCTGGGCCAGTG
TTGAAGCAGAAACGTTCTCTGATACGGGGCGTCTTCTCGTCTACTGTAAAGACCCGGTCAC
N F V F A R T M P A E G A D D I P G P V -
2685 ACCTGGGAGCCAAGGCCTGAAAACCTCCATCTTTTAAAGTGGCGGAACTGAGAAATCCC
TGGACCCCTCGGTTCCGGACTTTTGAGGTAGAAAAATTTACCGGCCCTTGGACTCTTAGGG
2744
T W E P R P E N S I F L K W P E P E N P -
2745 AATGGATTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAA
TTACCTAACTAAGATTACATACTTTATTTATGCTAGTGTCAACTCCTAGTCGCTCTT
2804
N G L I L M Y E I K Y G S Q V E D Q R E -

Fig. 3g

19/30

B
a
m
H
I
 ACCCGGATCCATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGTCC 219
 160 +-----+
 TGGGCCCTAGGTACTTCAGACCGAGGCTCTCTCCAGGGCTGGAGCGACACCCCCGAGG
 M K S G S G G S P T S L W G L L -
 TGTTCCTCTCCGCCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTCGGGGCCAGGCA 279
 220 +-----+
 ACAAGAGAGGGCGGCGAGAGCGAGACGGCTGCTCACCTCTTTAGACGCCCGGTCCGT
 F L S A A L S L W P T S G E I C G P G I -
 TCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGG 339
 280 +-----+
 AGCTGTAGGCGTTGCTGATAGTCGTCGACTTCGGGACCTCTTGACGTGCCACTAGCTCC
 D I R N D Y Q Q L K R L E N C T V I E G -
 GCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCA 399
 340 +-----+
 CGATGGAGGTGTAGGACGAGTAGAGGTTCCGGCTCCTGATGGCGTCGATGGCGAAGGGGT
 Y L H I L L I S K A E D Y R S Y R F P K -
 AGCTACGGTCATTACCGAGTACTTGCTGTGTTCAGTGGCTGGCCTCGAGAGCCTCG 459
 400 +-----+
 TCGAGTCCCAGTAATGGCTCATGAACGACGACAAGGCTCACCGACCGGAGCTCTCGGAGC
 L T V I T E Y L L L F R V A G L E S L G -
 GAGACCTCTTCCCCAACCTCAGGGTCATCCGGGGCTGGAACTCTTCTACAACCTACGCCC 519
 460 +-----+
 CTCTGGAGAAGGGGTGGAGTGCCAGTAGCGGCCGACCTTTGAGAAGATGTTGATGCGGG
 D L F P N L T V I R G W K L F Y N Y A L -

Fig. 4a

20/30

520 TGGTCATCTTCGAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTA 579
+-----+-----+-----+-----+-----+-----+-----+-----+
ACCAGTAGAAGCTCTACTGGTTAGAGTTCCCTATAACCCGAAATGTTGGACTCCTTGTAAT
V I F E M T N L K D I G L Y N L R N I T -
580 CTCGGGGGGCCATCAGGATTGAGNAATAATGCTGACCTCTGTACCTCTCCACTGTGGACT 639
+-----+-----+-----+-----+-----+-----+-----+-----+
GAGCCCCCGGTAGTCCTAACTCTTTTACGACTGGAGACAATGGAGAGGTGACACCTGA
R G A I R I E K N A D L C Y L S T V D W -
640 GGTCCCTGATCCTGGATGCGGTGTCCCAATAACTACATTGTGGGAATAAGCCCCCAAAGG 699
+-----+-----+-----+-----+-----+-----+-----+-----+
CCAGGACTAGGACCTACGCCACAGGTTATTGATGTAAACCCCTTATTCGGGGGTTTCC
S L I L D A V S N N Y I V G N K P P K E -
700 AATGTGGGACCTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAAGACCACCA 759
+-----+-----+-----+-----+-----+-----+-----+-----+
TTACACCCCTGGACACAGGTCCCTGGTACCTCCTCTTCGGCTACACACTCTTCTGSGTGT
C G D L C P G T M E E K P M C E K T T I -
760 TCAACAATGAGTACAACCTACCGCTGCTGGACCACAACCCGCTGCCAGAAAATGTGCCCAA 819
+-----+-----+-----+-----+-----+-----+-----+-----+
AGTTGTTACTCATGTTGATGGCGACGACCTGGTGTGTTGGCGACGGTCTTTTACACGGGTT
N N E Y N Y R C W T T N R C Q K M C P S -
820 GCACGTGTGGGAAGCGGGGTGCACCGAGAACAAATGAGTGTGCCACCCGAGTGCCTGG 879
+-----+-----+-----+-----+-----+-----+-----+-----+
CGTGACACCCCTTCGCCCGCACGTGGCTCTTGTACTACGACGGTGGGGCTCACGGACC
T C G K R A C T E N N E C C H P E C L G -

Fig. 4b

21/30

```

      880  GCAGCTGCAGCGCGCTGACAAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATG  939
            +-----+-----+-----+-----+-----+-----+-----+
      940  CGTCGACGTCGCGCGGACTGTTGCTGTGCCGGACACATCGAACGGCGGTGATGATGATAC
            +-----+-----+-----+-----+-----+-----+-----+
            S C S A P D N D T A C V A C R H Y Y A -
      999  CCGGTGTCTGTGCTGCCTGCCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTG
            +-----+-----+-----+-----+-----+-----+-----+
            G C C A G A C A C G G A C G G G G T T G T G G A T G T C C A A A C T C C G A C C G C G A C
            1000  G V C V P A C P P N T Y R F E G W R C V -
            +-----+-----+-----+-----+-----+-----+-----+
            TGGACCGTGACTTCTGCGCCAAACATCCTCAGCGCCGAGAGCAGCAGCTCCGAGGGGTTTG
            1059  ACCTGGCACTGAAGACGCGGTTGTAGGAGTCGCGGCTCTCGTCGCTGAGGCTCCCCAAC
            +-----+-----+-----+-----+-----+-----+-----+
            D R D F C A N I L S A E S S D S E G F V -
            1060  TGATCCACGACGGCGAGTGCATGCAGGAGTGCCCCCTCGGGCTTCATCCGGAATTCACAGCA
            +-----+-----+-----+-----+-----+-----+-----+
            ACTAGGTGCTGCCGCTCAGGTACGTCTCAGGGGAGCCCGAAGTAGGCCTTAAGGTCGT
            1119  I H D G E C M Q E C P S G F I R N S S N -
            +-----+-----+-----+-----+-----+-----+-----+
            1120  ACTTGTGTGACCCCATGCCCTGGGTCCCTGTGCCAAGGTGTGCCACCTCCTAGAAAGCG
            +-----+-----+-----+-----+-----+-----+-----+
            TGAACGACACGTGGGGTACGGACCCAGGGACAGGGTTCACACCGGTGGAGGATCTTCCCG
            1179  L L C T P C L G P C P K V C H L L E G E -
            +-----+-----+-----+-----+-----+-----+-----+
            1180  AGAAGACCATCGACTCGGTGACGTCTGCCCGAGGAGTCCGAGGATGCACCGTCATCAACG
            +-----+-----+-----+-----+-----+-----+-----+
            TCTTCTGGTAGCTGAGCCACTGCAGACGGGTCTCGAGGCTCCTACGTGGCAGTAGTTGC
            1239  K T I D S V T S A Q E L R G C T V I N G -
            +-----+-----+-----+-----+-----+-----+-----+

```

Fig. 4c

22/30

```

1240  GGAGTCTGATCATCAACATTGAGGAGGCAACAATCTGGCAGCTGAGCTAGAAGCCAACC
      CCTCAGACTAGTAGTTGTAAGCTCCTCCGTTGTTAGACCGTCGACTCGATCTTCGGTTGG
      S L I I N I R G G N N L A A E L E A N L -
1300  TCGGCCTCATTTGAAGAAATTTGAGGTATCTAATAATCCGCCGATCCTACGCTCTGGTGT
      AGCCGGAGTAACCTTCTTTAAAGTCCCATAGATTTTAGGCGGCTAGGATCGGAGACCACA
      G L I E E I S G Y L K I R R S Y A L V S -
1360  CACTTTCCTTCTCCGGAAGTTACCTCTGATTCGAGGAGAGACCTTGGAAATTTGGGAACCT
      GTGAAGGAAGAAGGCCCTTCAATGCAGACTAAGCTCCTCTCTGGAACCTTTAACCCTTGA
      L S F F R K L R L I R G E T L E I G N Y -
1420  ACTCCTTCTATGCCCTTGGACAACCAAGAACCTAAGGCAGCTCTGGGACTGGAGCAAAACACA
      TGAGGAAGATACGGAACCTGTTGGTCTTGGATTCCGTCGAGACCCCTGACCTCGTTTGTGT
      S F Y A L D N Q N L R Q L W D W S K H N -
1480  ACCTCACCACCACTCAGGGGAAACTCTTCTCCACTATAACCCCAACTCTGCTTGTCTAG
      TGGAGTGGTGGTGGTCCCTTTGAGAAGAAGGTGATATTGGGGTTTGAGACGGAACAGTC
      L T T T Q G K L F F H Y N P K L C L S E -
1540  AAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGCGCCAGGAGAGAACGACATTC
      TTTAGGTGTTCTACCTTCTCAAGTCTTGGTTCCTCCCGCGGTCTCTCTTTGCTGTAAAC
      I H K M E E V S G T K G R Q E R N D I A -

```

Fig. 4d

23/30

1600 CCCTGAAGACCAATGGGGACAAGGCATCCTGTGAAATGAGTTACTTAAATTTCTTACA 1659
+-----+-----+-----+-----+-----+-----+
GGGACTTCTGGTTACCCCTGTTCGGTAGGACACTTTTACTCAATGAATTTAAAGAATGT
L K T N G D K A S C E N E L L K F S Y I -
1660 TTCGGACATCTTTTGACAAGATCTTGCTGAGATGGAGCCGCTACTGGCCCCCGACTTCC 1719
+-----+-----+-----+-----+-----+-----+
AAGCCTGTAGAAAACTGTTCTAGAACGACTCTACCCCTCGGCATGACCGGGGGGCTGAAGG
R T S F D K I L L R W E P Y W P P D F R -
1720 GAGACCTCTTGGGGTTCATGCTGTTCTACAAGAGGCCCTTATCAGAAATGTGACGGAGT 1779
+-----+-----+-----+-----+-----+-----+
CTCTGGAGAACCCCAAGTACGACAAGATGTTTCTCCGGGGAATAGTCTTACACTGCCCTCA
D L L G F M L F Y K E A P Y Q N V T E F -
1780 TCGATGGGCAGGATCGTGTGTTCCAAACAGTTGGACGGTGGTAGACATTGACCCACCCC 1839
+-----+-----+-----+-----+-----+-----+
AGTACCCGTCCTACGCACACCAAGGTTGTCAACCTGCCACCACCATCTGTAACTGGGTGGG
D G Q D A C G S N S W T V V D I D P P L -
1840 TGAGGTCCAACGACCCCAAAATCACAGAACCAACCAGGGTGGCTGATCGGGGGTCTCAAGC 1899
+-----+-----+-----+-----+-----+-----+
ACTCCAGGTTGCTGGGGTTTAGTGTCTTGGTGGTCCCACCGACTACGCCCCAGAGTTCTG
R S N D P K S Q N H P G W L M R G L K P -
1900 CCTGGACCCAGTATGCCATCTTTGTGAAGACCCCTGGTCACCTTTTCGGATGAACGCCCGGA 1959
+-----+-----+-----+-----+-----+-----+
GGACCTGGGTACATACGGTAGAAACACTTCTGGGACCAGTGGAAAAGCCTACTTGGCGGCT
W T Q Y A I F V K T L V T F S D E R R T -

Fig. 4e

24/30

1960 CCTATGGGGCCAGAGTGACATCATTTATGTCCAGACAGATGCCACCAACCCCTCTGTGC
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
GGATACCCCGGTTCTCACTGTAGTAAATACAGGCTGTCTACGGTGGTTGGGAGACACG
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
Y G A K S D I I Y V Q T D A T N P S V P -

B
a
m
H
I

2020 CCCTGGATCCCAATCTCAGTGTCTAACTCATCATCCAGATTATTTCTGAAGTGGAACAC
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
GGACCTAGGTTAGAGTCACAGATTGAGTAGTAGGGTCTAATAAGACTTCACCTTTGGTG
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
L D P I S V S N S S Q I I L K W K P -

2080 CCTCCGACCCCAATGGCAACATCACCCTACCTGGTTTTCTGGGAGAGGCGCGGAAG
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
GGAGGCTGGGGTTACCGTTGTAGTGGGTGATGGACCAAAAGACCTCTCCGTCCGCCTTC
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
S D P N G N I T H Y L V F W E R Q A E D -

2140 ACAGTGAGCTGTTTCGAGCTGGATTATTGCTCAAGGGCTGAAGCTGCCCTCGAGGACCT
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
TGTCACTCGACAAGCTCGACCTAATAACGGAGTTTCCCGACTTCGACGGGGAGCTCCTGGA
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
S E L F E L D Y C L K G L K L P S R T W -

2200 GGTCTCCACCATTCGAGCTCTGAAGATTCTCAGAAGCACCAACAGAGTGAGTATGAGGATT
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
CCAGAGGTGGTAAGCTCAGACTTCTAAGAGTCTTCGTGTGGTCTCACTCACTACTCTAA
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
S P P F E S E D S Q K H N Q S E Y E D S -

2260 CGGCCGGGGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTGAAGGAGCTGGAGG
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
GCCGGCCGCTTACGACGAGGACAGGTTTCTGTCTGAGAGTCTAGGACTTCTCCTGACCTCC
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
A G E C C S C P K T D S Q I L K E L E E -

Fig. 4f

25/30

2320 AGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTTGGTTTTCGTCCCCAGAA 2379
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
TCAGGAGCAAAATCCTTCTGCAAACTCCTAATGGACGTGTTGCACCAAAAGCAGGGGTCTT
S S F R K T F E D Y L H N V V F V P R K -
2380 AAACCTCTTCAGGCACTGGTGCCGAGGACCCCTAGGCCATCTCGGAACGCAGGTCCCTTG 2439
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
TTTGAGAGAAGTCCGTGACCACGGCTCCTGGGATCCGGTAGAGCCTTTGCCGTCCAGGGAAAC
T S S G T G A E D P R P S R K R S L G -
2440 GCGATGTTGGGAATGTGACGGTGCGGTGCCGCCACGGTGGCAGCTTTCCCAACACTTCCT 2499
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
CGCTACAACCCCTTACACTGCCACCGGCACGGGTGCCACCGTCGAAAGGGGTTGTGAAGGA
D V G N V T V A V P T V A A F P N T S S -
2500 CGACGAGCGTGCCCAAGTCCGGAGGAGCACAGGCCCTTTTGAGAAGGTGCTGAACAAGG 2559
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
GCTGGTCGCACGGGTGCTCAGGCCCTCCTCGTGTCCGGAAAACCTTCCACCACTTGTTC
T S V P T S P E E H R P F E K V V N K E -
2560 AGTCGCTGGTCATCTCCGGCTTGGGACACTTCACGGGCTATCGCATCGAGCTGCAGGCTT 2619
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
TCAGCGACCAAGTAGAGGCCGAACGCTGTGAAGTGCCCGATAGCGTAGCTCGACGTCGCGAA
S L V I S G L R H F T G Y R I E L Q A C -
2620 GCAACCAAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTACGTGCGGAGGACCA 2679
+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
CGTTGGTCCCTGTGGGACTCCTTGCCACGTCACACCCGTCGGATGCGATCAGTCACGCTCCTGGT
N Q D T P E E R C S V A A Y V S A R T M -

Fig. 4g

26/30

```

2680 +-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
      TGCCTGAAGCCAAAGGCTGATGACATTTGTTGGCCCTGTGACGCATGAAATCTTTGAGAACAA 2739
      ACGGACTTCGGTTCCGACTACTGTAACAACCGGGACACTGCGTACTTTAGAAACTCTTGT
      P E A K A D D I V G P V T H E I F E N N -
2740 +-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
      ACGTCGTCCACTTGATGTGGCAGGAGCCGAAGAGCCCCAATGGTCTGATCGTGTGTATG
      TGCAGCAGGTGAACACTACACCGTCCTCGGCTTCTCGGGTTACAGACTAGCACACATAC 2799
      V V H L M W Q E E P K E P N G L I V L Y E -
2800 +-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
      AAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTCTCCCGCAAGCACT
      TTCACCTCAATAGCCGCTATACCACCTACTCCTCGACGTAGAGACGCGAGGGCGTTTCGTGA 2859
      V S Y R R Y G D E E L H L C V S R K H F -
2860 +-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
      TCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTACCGGGGAACTACAGCGTGCAGAA 2919
      AGCGAGACCTTGCCCGGACGTCCGACGCGCACCCGACAGTGGCCCCCTTGATGTGCGACGCTT
      A L E R G C R L R G L S P G N Y S V R I -
2920 +-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
      TCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACCTATTCTACGTGA
      AGCCCCGGTGGAGGGAACGCCCGTTGCCGAGAACCTGCCCTGGGTGGATAAAGATGCACT 2979
      R A T S L A G N G S W T E P T Y F Y V T -
                                     X
                                     b
                                     a
                                     I
2980 +-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
      CAGACTATTTAGACGTCCCGTCAATAATTGCAAAATAATCTAGAGGATCTGGGGTGGCAT
      GTCTGATAAATCTGCAGGCGAGTTATAACGTTTATATAGATCTCCTAGACCCACCGTA 3039
      D Y L D V P S N I A K * S R G S G V A S -

```

Fig. 4h

27/30

```

3040 CCCTGTGACCCCTCCAGTCCTCTCTGGCCCTGGAAGTTGCCACTCCAGTGCCCAAC 3099
      +-----+-----+-----+-----+-----+-----+
      GGGACACTGGGGAGGGTCAAGAGAGGACCGGGACCTTCAACGGTGAGGTCAAGGGTGG
      L * P L P S A S P G P G S C H S S A H Q -
3100 AGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTCTATAAT
      +-----+-----+-----+-----+-----+-----+
      TCGGAACAGGATTATTTAATTCAACGTAGTAAACACAGACTGATCCACAGGAAGATATTA 3159
      P C P N K I K L H H F V * L G V L L * Y -
3160 ATTATGGGGTGGAGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGG
      +-----+-----+-----+-----+-----+-----+
      TAATACCCACCTCCCCCCACCATACCTCGTTCCCGTTCAACCCCTTCTGTTGGACATCC 3219
      Y G V E G G G M E Q G A S W E D N L * G -
3220 GCCTGCGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCA
      +-----+-----+-----+-----+-----+-----+
      CGGACGCCCCAGATAACCCCTGGTTCGACCTCACGTCACCCGTTAGAACCGGAGTGACGT 3279
      L R G L L G T K L E C S G T I L A H C N -
3280 ATCTCCGCCCTCCTGGGTCAA
      +-----+-----+-----+-----+-----+-----+
      TAGAGCGGGAGGACCCCAAGTT 3300
      L R L L G S S -

```

Fig. 4i

28/30




Fig. 5

29/30




Fig. 6

30/30







Fig. 7

INTERNATIONAL SEARCH REPORT

International Application No PCT/DK 91/00116

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 12 N 15/62, 5/00																	
II. FIELDS SEARCHED <div style="text-align: center;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 25%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">IPC5</td> <td style="border: 1px solid black; padding: 5px;">C 12 N; C 07 K; A 61 K</td> </tr> </table> <div style="text-align: center; padding-top: 5px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched⁸</div>			Classification System	Classification Symbols	IPC5	C 12 N; C 07 K; A 61 K											
Classification System	Classification Symbols																
IPC5	C 12 N; C 07 K; A 61 K																
SE,DK,FI,NO classes as above																	
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category *</th> <th style="width: 70%;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 20%;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td>Proc. Natl. Acad. Sci. USA, Vol. 83, November 1986 L. Ellis et al.: "Linking functional domains of the human insulin receptor with the bacterial aspartate receptor", see page 8137 - page 8141 --</td> <td style="text-align: center; vertical-align: top;">1-29</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td>WO, A1, 8905355 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 15 June 1989, see the whole document --</td> <td style="text-align: center; vertical-align: top;">1-29</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td>EP, A1, 0244221 (GENENTECH, INC.) 4 November 1987, see the whole document --</td> <td style="text-align: center; vertical-align: top;">1-29</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td>The Journal of Cell Biology, Vol. 109, November 1989 L. Sistonen et al.: "Activation of the neu Tyrosine Kinase Induces the fos/jun Transcription Factor Complex, the Glucose Transporter, and Ornithine Decarboxylase", see page 1911 - page 1919 --</td> <td style="text-align: center; vertical-align: top;">28-29</td> </tr> </tbody> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	Y	Proc. Natl. Acad. Sci. USA, Vol. 83, November 1986 L. Ellis et al.: "Linking functional domains of the human insulin receptor with the bacterial aspartate receptor", see page 8137 - page 8141 --	1-29	Y	WO, A1, 8905355 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 15 June 1989, see the whole document --	1-29	Y	EP, A1, 0244221 (GENENTECH, INC.) 4 November 1987, see the whole document --	1-29	Y	The Journal of Cell Biology, Vol. 109, November 1989 L. Sistonen et al.: "Activation of the neu Tyrosine Kinase Induces the fos/jun Transcription Factor Complex, the Glucose Transporter, and Ornithine Decarboxylase", see page 1911 - page 1919 --	28-29
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
Y	Proc. Natl. Acad. Sci. USA, Vol. 83, November 1986 L. Ellis et al.: "Linking functional domains of the human insulin receptor with the bacterial aspartate receptor", see page 8137 - page 8141 --	1-29															
Y	WO, A1, 8905355 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 15 June 1989, see the whole document --	1-29															
Y	EP, A1, 0244221 (GENENTECH, INC.) 4 November 1987, see the whole document --	1-29															
Y	The Journal of Cell Biology, Vol. 109, November 1989 L. Sistonen et al.: "Activation of the neu Tyrosine Kinase Induces the fos/jun Transcription Factor Complex, the Glucose Transporter, and Ornithine Decarboxylase", see page 1911 - page 1919 --	28-29															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																	
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border: none;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">17th July 1991</td> <td style="border: 1px solid black; padding: 5px;">1991-07-25</td> </tr> <tr> <td style="border: none;">International Searching Authority</td> <td style="border: none;">Signature of Authorized Officer</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px; text-align: center;">SWEDISH PATENT OFFICE</td> <td style="border: 1px solid black; padding: 5px; text-align: center;">  Yvonne Siösteen </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	17th July 1991	1991-07-25	International Searching Authority	Signature of Authorized Officer	SWEDISH PATENT OFFICE	 Yvonne Siösteen							
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																
17th July 1991	1991-07-25																
International Searching Authority	Signature of Authorized Officer																
SWEDISH PATENT OFFICE	 Yvonne Siösteen																

Form PCT/ISA/210 (extra sheet) (January 1985)

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/DK 91/00116**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the Swedish Patent Office EDP file on **91-06-27**
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 8905355	89-06-15	AU-D- 2818889	89-07-05
		EP-A- 0325849	89-08-02
		US-A- 4981784	91-01-01
EP-A1- 0244221	87-11-04	JP-A- 62272990	87-11-27
		US-A- 4859609	89-08-22
EP-A2- 0325262	89-07-26	AU-D- 3281889	89-08-11
		WO-A- 89/06690	89-07-27